Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.

Publication ,  Journal Article
Russell, S; Lim, F; Peters, PN; Wardell, SE; Whitaker, R; Chang, C-Y; Previs, RA; McDonnell, DP
Published in: Cancers (Basel)
August 30, 2022

Despite advances in surgery and targeted therapies, the prognosis for women with high-grade serous ovarian cancer remains poor. Moreover, unlike other cancers, immunotherapy has minimally impacted outcomes in patients with ovarian cancer. Progress in this regard has been hindered by the lack of relevant syngeneic ovarian cancer models to study tumor immunity and evaluate immunotherapies. To address this problem, we developed a luciferase labeled murine model of high-grade serous ovarian cancer, STOSE.M1 luc. We defined its growth characteristics, immune cell repertoire, and response to anti PD-L1 immunotherapy. As with human ovarian cancer, we demonstrated that this model is poorly sensitive to immune checkpoint modulators. By developing the STOSE.M1 luc model, it will be possible to probe the mechanisms underlying resistance to immunotherapies and evaluate new therapeutic approaches to treat ovarian cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

August 30, 2022

Volume

14

Issue

17

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Russell, S., Lim, F., Peters, P. N., Wardell, S. E., Whitaker, R., Chang, C.-Y., … McDonnell, D. P. (2022). Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer. Cancers (Basel), 14(17). https://doi.org/10.3390/cancers14174219
Russell, Shonagh, Felicia Lim, Pamela N. Peters, Suzanne E. Wardell, Regina Whitaker, Ching-Yi Chang, Rebecca A. Previs, and Donald P. McDonnell. “Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.Cancers (Basel) 14, no. 17 (August 30, 2022). https://doi.org/10.3390/cancers14174219.
Russell S, Lim F, Peters PN, Wardell SE, Whitaker R, Chang C-Y, et al. Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer. Cancers (Basel). 2022 Aug 30;14(17).
Russell, Shonagh, et al. “Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.Cancers (Basel), vol. 14, no. 17, Aug. 2022. Pubmed, doi:10.3390/cancers14174219.
Russell S, Lim F, Peters PN, Wardell SE, Whitaker R, Chang C-Y, Previs RA, McDonnell DP. Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer. Cancers (Basel). 2022 Aug 30;14(17).

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

August 30, 2022

Volume

14

Issue

17

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis